Angios
Angios is an Austrian biotechnology company specializing in cell-based research and regenerative treatments for vascular diseases. Their mission is to develop innovative, animal-free models and therapies to improve patient outcomes, particularly in diabetic retinopathy and wound healing. They utilize unique technologies such as blood vessel organoids and vascular transplants to create scalable blood vessel factories and regenerative solutions. The company collaborates with partners like Abcellera Biologics and academic institutions to accelerate the development of novel therapeutics and models. Their work aims to address unmet medical needs in vascular health, diabetic blindness, and cardiovascular toxicity prediction.
Industries
Nr. of Employees
small (1-50)
Angios
Products
Blood vessel organoids (BVOs) for regenerative transplantation
iPSC-derived microvascular organoids intended as transplantable units to reconnect tissue to host blood supply and support wound healing.
Organoid-based drug screening platform
An in vitro platform using blood vessel organoids to assess vascular toxicity and generate a predictive toxicity score for drug candidates.
Blood vessel organoids (BVOs) for regenerative transplantation
iPSC-derived microvascular organoids intended as transplantable units to reconnect tissue to host blood supply and support wound healing.
Organoid-based drug screening platform
An in vitro platform using blood vessel organoids to assess vascular toxicity and generate a predictive toxicity score for drug candidates.
Services
In vitro testing services using blood vessel organoids to assess compound effects on human vasculature and generate predictive toxicity readouts.
Collaborative development to advance antibody targets for diabetic vasculopathies using organoid-derived discovery data.
In vitro testing services using blood vessel organoids to assess compound effects on human vasculature and generate predictive toxicity readouts.
Collaborative development to advance antibody targets for diabetic vasculopathies using organoid-derived discovery data.
Expertise Areas
- Organoid model development
- Vascular regenerative medicine
- iPSC-based tissue engineering
- In vitro drug screening for vascular toxicity
Key Technologies
- Induced pluripotent stem cell (iPSC) differentiation
- Blood vessel organoids (BVOs)
- 3D tissue engineering of microvasculature
- Organoid-based toxicity assays
News & Updates
Angios announced their plans to build a biotech cluster in Innsbruck, Austria.
Angios aims to replace animal testing with their innovative blood vessel models.
Highlighting the versatility and applications of organ models developed by Angios.
Partnership to develop new therapies and technologies in vascular medicine.
Further details on the biotech development in Innsbruck.
Discussion on the increasing importance of organoids in medical research and regenerative medicine.
Angios announced their plans to build a biotech cluster in Innsbruck, Austria.
Angios aims to replace animal testing with their innovative blood vessel models.
Highlighting the versatility and applications of organ models developed by Angios.
Partnership to develop new therapies and technologies in vascular medicine.
Further details on the biotech development in Innsbruck.
Discussion on the increasing importance of organoids in medical research and regenerative medicine.